215 related articles for article (PubMed ID: 27315793)
1. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract][Full Text] [Related]
2. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Hou GX; Liu P; Yang J; Wen S
PLoS One; 2017; 12(3):e0174515. PubMed ID: 28355294
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. Mining topoisomerase isoforms in gastric cancer.
Hou G; Deng J; You X; Chen J; Jiang Y; Qian T; Bi Y; Song B; Xu Y; Yang X
Gene; 2020 Sep; 754():144859. PubMed ID: 32535049
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
6. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
Zhou X; Teng L; Wang M
Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
[TBL] [Abstract][Full Text] [Related]
7. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
11. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
[TBL] [Abstract][Full Text] [Related]
12. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
13. The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S; Hu X; Ye M; Zhu X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
[No Abstract] [Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of S100 family members in ovarian cancer patients.
Bai Y; Li LD; Li J; Lu X
BMC Cancer; 2018 Dec; 18(1):1256. PubMed ID: 30558666
[TBL] [Abstract][Full Text] [Related]
17. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
19. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
20. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
